Kisqali and Dyspnea - a phase IV clinical study of FDA data

Summary:

Dyspnea is reported as a side effect among people who take Kisqali (ribociclib succinate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Letrozole, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Dyspnea when taking Kisqali. It is created by eHealthMe based on reports of 25,037 people who have side effects when taking Kisqali from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,049 Kisqali users. Check the latest studies of Kisqali.

What is Dyspnea?

Dyspnea (difficult or laboured breathing) is found to be associated with 3,717 drugs and 6,067 conditions by eHealthMe. Check the latest studies of Dyspnea.

On Jul, 19, 2026

25,037 people reported to have side effects when taking Kisqali.
Among them, 1,614 people (6.45%) have Dyspnea.

Among these 1,614 people:

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and have Dyspnea?

- Check whether Dyspnea is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kisqali:

Kisqali (25,049 reports)

Dyspnea treatments and more:

Dyspnea (661,578 reports)

How severe was Dyspnea and when was it recovered:

Dyspnea in Kisqali

Expand to all the drugs that have ingredients of ribociclib succinate:

Dyspnea and drugs with ingredients of ribociclib succinate (1,672 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dyspnea:

Dyspnea (3,717 drugs)

Browse all the conditions that are associated with Dyspnea:

Dyspnea (6,067 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate (the active ingredients of Kisqali) and Kisqali (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.